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1940Objective: The study objective was to determine whether the new-generation Trifecta (St Jude Medical Inc,
St Paul, Minn) bovine aortic valve bioprosthesis, which is designed for supra-annular positioning, produces early
postoperative hemodynamic results comparable to or better than those of the Mitroflow (Sorin Group, Milan,
Italy) or Perimount Magna (Edwards Lifesciences Corp, Irvine, Calif) bovine aortic valve bioprostheses.
Methods:We retrospectively reviewed the medical records of patients who underwent aortic valve replacement
with a Trifecta, Mitroflow, or Perimount Magna bovine pericardial prosthesis at Mayo Clinic between June 2007
andDecember 2012 and analyzed early postoperative hemodynamic performance byDoppler echocardiography.
Results: A total of 1436 patients underwent aortic valve replacement (Trifecta in 196, Mitroflow in 1135, Peri-
mount Magna in 105). Preoperative characteristics and early clinical outcomes were similar among the 3 valve
groups. The average mean gradients were lower and valve areas were greater with the Trifecta valves. For the
Trifecta, Mitroflow, and PerimountMagna valves, the averagemean gradient was 11.4 mmHg, 16.9 mmHg, and
14.1 mm Hg, respectively; the effective orifice area was 2.22 cm2, 1.85 cm2, and 2.09 cm2, respectively; and the
indexed effective orifice area was 1.14 cm2/m2, 0.96 cm2/m2, and 1.07 cm2/m2, respectively (all P< .001).
Similar statistical significance was found when data were stratified by valve size. Severe prosthesis–patient
mismatch (indexed effective orifice area<0.60 cm2/m2) was detected in 1.3% of patients (n ¼ 2/150) with
the Trifecta, 5.8% of patients (n ¼ 44/758) with the Mitroflow, and 3.2% of patients (n ¼ 3/95) with the
Perimount Magna (P ¼ .048).
Conclusions: Early hemodynamic postoperative performance of the Trifecta bioprosthesis is favorable.
Additional follow-up should determine whether these small hemodynamic differences will persist and influence
later clinical outcomes. (J Thorac Cardiovasc Surg 2014;148:1940-6)Bioprosthetic valves are recommended for patients agedmore
than 65 years who require valve replacement and for patients
who have medical contraindications to systemic anticoagula-
tion or who prefer to avoid warfarin because of lifestyle
considerations.1 Stented bovine pericardial prostheses are
considered to have better hemodynamic results (lower gradi-
ents) than stented porcine valves.2-4 The Mitroflow (Sorin
Group, Milan, Italy) bovine bioprosthesis and the Perimount
Magna (Edwards Lifesciences Corp, Irvine, Calif) bovine
bioprosthesis have been used in clinical practice with
favorable outcomes since 1982 and 2003, respectively.4-7e Division of Cardiovascular Surgery, Mayo Clinic, Rochester, Minn.
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The Journal of Thoracic and Cardiovascular SurThe Trifecta aortic valve (St Jude Medical Inc, St Paul,
Minn) is a new bovine bioprosthesis approved in 2011
that incorporates ethanol-based anticalcification technol-
ogy. Recent reports have documented satisfactory early-
term (predischarge to 1-2 years) clinical and hemodynamic
performance after aortic valve replacement (AVR) using the
Trifecta valve.8,9 Dell’Aquila and colleagues10 compared
AVR outcomes for the Trifecta with previously published
data and found lower mean gradients at hospital discharge.
Wendt and colleagues11 reported that their comparison of
the 6-month hemodynamics of the Trifecta valve and the
Perimount Magna and Magna Ease valves (Edwards Life-
sciences Corp) indicated that mean pressure gradients and
aortic valve areas seemed better with the Trifecta, but multi-
variate covariance analysis showed no influence of pros-
thesis type on either variable. In this study, we compared
the early hemodynamic outcomes of the new generation
Trifecta valve bioprosthesis with those of the widely used
Mitroflow and PerimountMagna aortic valve bioprostheses.MATERIALS AND METHODS
In this retrospective study, after obtaining approval from the Mayo
Clinic Institutional Review Board, we searched the institutional
cardiovascular surgery database to identify all patients who had undergone
AVR between January 2007 and December 2012. We included all patientsgery c November 2014
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
EOA ¼ effective orifice area
EOAI ¼ effective orifice area index
LVOT ¼ left ventricular outflow tract
PPM ¼ prosthesis–patient mismatch
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records for research purposes and who had undergone AVR with the
Trifecta, Mitroflow, or Perimount Magna bovine pericardial valve
bioprosthesis. Demographic and clinical information, including early
mortality and echocardiographic reports, were abstracted from medical
records and the Mayo Clinic Cardiovascular Surgery Clinical Database.
We compared preoperative clinical characteristics, operative data, and
early postoperative hemodynamic outcomes of patients.
Operations were performed using standard cardiopulmonary bypass and
cold-blood cardioplegic cardiac arrest. After aortotomy and excision of
the diseased aortic valve, the decisions regarding surgical technique and
valve type were made by the operating surgeon. Choice of valve was
made by the surgeon, and this selection was not based on clinical or
anatomic considerations. AVRwas performedwith interrupted noneverting
pledget-reinforced sutures after measurement of the aortic annulus with
valve-sizers supplied by manufacturers. The aortotomy was closed using
primary suture or patch closure, as necessary.
The Trifecta valve is a completely supra-annular–positioned pericardial
aortic valve constructed from a single bovine pericardial sheet externally
mounted on a titanium stent and a sewing ring.8,10 It has been in clinical
use in the United States since 2007. The Mitroflow valve is a
glutaraldehyde-fixed bovine pericardial bioprosthesis constructed with
bovine pericardium mounted on the outside of a flexible polyester-
covered acetyl homopolymer stent and sutured into place.12,13 The valve
has been used in Europe since 1987 and in the United States since 2007.
The Perimount Magna valve is a modification of the Perimount valve,
and it has been used since 2002. It is mounted on an Elgiloy (Elgin, Ill)
frame, and, in addition to glutaraldehyde fixation, the bovine pericardial
cusps are treated with surfactant and thermal exposure to retard
calcification.3
All patients underwent 2-dimensional and Doppler transthoracic echo-
cardiographic examinations preoperatively and before discharge from the
hospital. Standard prosthetic valve measurements were evaluated,
including mean gradient, effective orifice area (EOA), and effective orifice
area index (EOAI). The mean aortic valve gradient was measured using
continuous-wave Doppler velocity spectra from the transducer position
that yielded maximum velocity across the valve or prosthesis and was
calculated by the modified Bernoulli equation. EOA was calculated
automatically from the continuity equation by using the left ventricular
outflow tract (LVOT) area and the time velocity integral. The EOAI was ob-
tained by dividing the EOA by the body surface area. Prosthesis–patient
mismatch (PPM) was evaluated as severe if the EOAI was 0.60 cm2/m2
or less.14
Statistical Methods
Descriptive statistics are reported as number (percentage) for categoric
variables and as mean (standard deviation) or median (range) for contin-
uous variables, as appropriate. The categoric variables of the patients
with Trifecta, Mitroflow, or Perimount Magna bioprostheses were
compared using the chi-square test, and the continuous variables were
compared using the analysis of variance or the Kruskal–Wallis test, as
appropriate. All statistical tests were 2-sided.The Journal of Thoracic and CarRESULTS
A total of 3896 patients underwent AVR at Mayo Clinic,
Rochester,Minnesota, from June 2007 toDecember 2012. A
total of 990 patients received mechanical prostheses, 2876
patients received bioprostheses, and 30 patients received
homografts. We evaluated 1436 patients who underwent
AVR with the Trifecta (196 [14%]), Mitroflow (1135
[79%]), or Perimount Magna (105 [7%]) bioprosthesis.
Of these 1436 patients, most (1315 [91.6%]) had severe
aortic valve stenosis and one fourth (373 [26.0%]) had
moderate or severe aortic valve regurgitation. The baseline
characteristics of the 1436 patients and their preoperative
echocardiographic findings are detailed in Table 1. The
mean LVOT diameter, as measured on preoperative trans-
thoracic echocardiograms, was 2.3  0.3 cm, 2.26  0.20
cm, and 2.27  0.20 cm in the Trifecta, Mitroflow, and
Perimount Magna valves, respectively (P ¼ .22), and was
statistically indistinguishable among implant groups.
Concomitant coronary artery bypass grafting and other
valve surgeries were performed more frequently in patients
with the Mitroflow (P<.001), but there was no difference in
use of annular enlargement among the 3 groups (P ¼ .73).
Concomitant surgical procedures are shown in Table 2. In
the Mitroflow group, crossclamp and perfusion times
were slightly longer than those in the Trifecta and Peri-
mount Magna groups (for isolated AVR, 62  27 minutes,
53  30 minutes, and 55  26 minutes, respectively;
P<.001). Thirty-day mortality and neurologic event rates
were similar among groups; for the Trifecta, Mitroflow,
and Perimount Magna groups, there were 3 early deaths
(1.5%), 34 early deaths (3.0%), and 1 early death (1%)
(P ¼ .27), respectively, and 3 strokes (1.5%), 17 strokes
(1.5%), and no strokes (P ¼ .45), respectively (Table 3).
For the Trifecta, Mitroflow, and Perimount Magna
groups, the mean transprosthetic gradient on predischarge
postoperative echocardiograms at a mean of 4.7  2.6
days after operation was 11.4 mm Hg, 16.9 mm Hg, and
14.1 mm Hg, respectively (P < .001); prosthetic valve
EOA was 2.22 cm2, 1.85 cm2, and 2.09 cm2, respectively
(P<.001); and EOAI was 1.14 cm2/m2, 0.96 cm2/m2, and
1.07 cm2/m2, respectively (P<.001) (Table 4). Similar sta-
tistical significance was found when data were stratified by
labeled valve size (Figure 1).
The rate of severe PPM after implantation of the Trifecta,
Mitroflow, and Perimount Magna valves was 1.3% (2/150),
5.8% (44/758), and 3.2% (3/95), respectively, for all pa-
tients (P ¼ .048), and 2.1% (2/97), 7.2% (25/347), and
3.4% (2/59) (P¼ .11), respectively, for patients undergoing
isolated AVR.DISCUSSION
To our knowledge, this is the first study to compare early
postoperative outcomes for the more recently approveddiovascular Surgery c Volume 148, Number 5 1941
TABLE 1. Characteristics of 1436 patients who underwent aortic valve replacement with 1 of 3 bovine bioprostheses*
Variable
Bioprosthesis (N ¼ 1436)
P value
Trifecta (St Jude Medical,
St Paul, Minn) (n ¼ 196)
Mitroflow (Sorin Group,
Milan, Italy) (n ¼ 1135)
Perimount Magna
(Edwards Lifesciences Corp,
Irvine, Calif) (n ¼ 105)
Age, y 74.5  8.5 75  9.6 75.4  7.6 .55
Male sex 129 (65.8) 695 (61.2) 66 (62.9) .47
BMI, kg/m2 29.3  5.5 29.7  6.2 29.6  6.2 .90
BSA 1.97  0.2 1.95  0.2 1.96  0.3 .54
Smoking 49/88 (55.7) 455/820 (55.5) 50/95 (52.6) .87
Medical history
Hypertension 152/195 (77.9) 890 (78.4) 74 (70.5) .16
Diabetes mellitus 45 (23.1) 311 (27.4) 28 (26.7) .45
Dialysis-dependent RF 1 (0.5) 18 (1.6) 1 (1) .46
Myocardial infarction 26 (13.3) 190 (16.7) 13 (12.4) .28
Cardiac surgery 27 (13.8) 219 (19.3) 13 (12.4) .05
Previous CABG 17 (8.7) 158 (13.9) 11 (10.5) .10
Atrial fibrillation 19 (9.7) 143 (12.6) 6 (5.7) .07
Risk factors
CVA 11/47 (23.4) 69/240 (28.8) 4/19 (21.1) .61
PVD 14/195 (7.2) 152 (13.4) 8 (7.6) .02
COPD 22/195 (11.3) 239 (21.1) 23 (21.9) .006
Aortic stenosis 175 (89.3) 1037 (91.4) 103 (98.1) .03
Aortic regurgitation 57 (34.1) 302 (30.9) 14 (16.5) .01
Preoperative echocardiographic results
Ejection fraction,% 60.81  10.7 59.07  13.5 60.09  11.3 .87
LVOT diameter, cm 2.3  0.3 2.26  0.2 2.27  0.2 .22
Mean gradient, mm Hg 47.91  17.5 47.08  16.9 50.65  14.4 .08
EOA, cm2 1.11  0.8 1.04  0.7 0.92  0.4 .50
EOAI, cm2/m2 0.48  0.2 0.47  0.2 0.47  0.2 .83
AV, Aortic valve; BMI, body mass index; BSA, body surface area; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular
accident; EOA, effective orifice area; EOAI, effective orifice area index; LVOT, left ventricular outflow tract; PVD, peripheral vascular disease; RF, renal failure. *Values are
number (percentage) or mean  standard deviation unless indicated otherwise.
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mount Magna aortic valves, which have been in use longer.
Mean gradients were slightly lower, and EOA and EOAI
were greater in the Trifecta group than in the Perimount
Magna and Mitroflow groups, as assessed by early postop-
erative hemodynamic data before hospital discharge.
Similar results were obtained when data were stratified by
commercially labeled valve size.TABLE 2. Concomitant surgical procedures in 1436 patients who underw
Procedure
Bi
Trifecta (n ¼ 196) Mitro
Aortic annular enlargement 5 (2.6)
Ascending aorta graft replacement 5 (2.6)
Myectomy 11 (5.6)
Concomitant CABG 56 (28.6)
Mitral valve repair 3 (1.5)
Mitral valve replacement 0 (0.0)
Tricuspid valve repair 6 (3.1)
Tricuspid valve replacement 4 (2.0)
Atrial septal defect 2 (1.0)
CABG, Coronary artery bypass grafting. *Values are number (percentage).
1942 The Journal of Thoracic and Cardiovascular SurEach of the 3 valves studied was designed for supra-
annular positioning, which facilitates implantation in small
annuli and reduces or eliminates the need for other surgical
alternatives, such as stentless heterografts or homografts
and root enlargement procedures to avoid PPM.1,15,16
Stentless devices have been associated with a 20% rate of
failure at 10-year follow-up,1,10,17 and reoperation may
require aortic root replacement, with increased mortalityent aortic valve replacement with 1 of 3 bovine bioprostheses*
oprosthesis (N ¼ 1436)
P valueflow (n ¼ 1135) Perimount Magna (n ¼ 105)
44 (3.9) 4 (3.8) .73
43 (3.8) 0 (0.0) .07
88 (7.8) 0 (0.0) .001
499 (44.0) 38 (36.2) <.001
37 (3.3) 2 (1.9) .43
71 (6.3) 0 (0.0) <.001
79 (7.0) 1 (1) .005
19 (1.7) 0 (0.0) .39
62 (5.5) 0 (0.0) <.001
gery c November 2014
TABLE 3. Comparison of operative findings in 1436 patients who underwent aortic valve replacement with 1 of 3 bovine bioprostheses*
Variable
Bioprosthesis (N ¼ 1436)
P valueTrifecta (n ¼ 196) Mitroflow (n ¼ 1135) Perimount Magna (n ¼ 105)
Isolated AVR 129 (65.8) 521 (45.9) 65 (61.9) <.001
Concomitant valve surgery 13 (6.6) 173 (15.2) 2 (1.9) <.001
CPB time, min 83  52 110  57 86  48 <.001
CPB time for isolated AVR, min 67  40 83  43 71  38 <.001
XCL time, min 66  41 82  40 68  34 <.001
XCL time for isolated AVR, min 53  30 62  27 55  26 <.001
Reoperation for bleeding 4 (2.0) 51 (4.5) 6 (5.7) .22
Reoperation for bleeding for isolated AVR 4/196 (3.1) 13/521 (2.5) 3/65 (4.6) .60
Low CO 1 (0.5) 27 (2.4) 0 (0) .07
Mortality, 30 d 3 (1.5) 34 (3.0) 1 (1) .27
Mortality, 30 d, for isolated AVR 2/129 (1.6) 6/521 (1.2) 0/65 (0) .62
Stroke 3 (1.5) 17 (1.5) 0 (0) .45
Stroke for isolated AVR 1/129 (0.8) 4/521 (0.8) 0/65 (0) .78
TIA 1/171 (0.6) 9/1112 (0.8) 0 (0) .63
TIA for isolated AVR 1/113 (0.9) 3/511 (0.6) 0 (0) .76
AVR, Aortic valve replacement; CO, cardiac output; CPB, cardiopulmonary bypass; TIA, transient ischemic attack; XCL, aortic crossclamp. *Values are number (percentage) or
mean  standard deviation unless indicated otherwise.
Ugur et al Acquired Cardiovascular Disease
A
C
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age-related risk of structural valve deterioration.18 Supra-
annular positioning of bioprostheses is thought to improve
hemodynamic outcomes by minimizing stent and sewing
ring interference with left ventricular ejection.9,15
These 3 pericardial valves are all being used in current
clinical practice. The Mitroflow valve has satisfactory
EOA and hemodynamic performance, and studies show
that its rate of failure requiring replacement is 3.7% to
4.1% at 20 years and that the rate of freedom from valve-
related death is 82.9% to 89.1%.6,7 In US studies, the
3-year actuarial freedom from valve-related death, reopera-
tion, and structural dysfunction has been reported as 97.0%,
97.9%, and 99.2%, respectively.13 In this early follow-up,
primary reasons for explantation were structural valve
deterioration and endocarditis; 3-year valve-related events
were similar to those for other bioprosthetic valves.13
The Perimount Magna valve has been shown to have
lower postoperative gradients and greater EOA and EOAI
than the earlier-generation Perimount valve.19 In early
hemodynamic studies, this prosthesis may have slightly
lower gradients and similar valve areas than the Mitroflow
and the Epic (St Jude Medical) prostheses.20
The Trifecta valve is a relatively new prosthesis with few
data available yet on clinical and hemodynamic outcomes.
Two-year follow-up data from a multicenter trial demon-
strated that freedom from valve-related mortality, prosthetic
valve endocarditis, and explantation was 99.4%, 98.6%,
and 99.4%, respectively.8 In a series of 200 patients, Per-
manyer and associates9 reported satisfactory hemodynamic
results for the Trifecta aortic valve prosthesis and no
cases of PPM. As mentioned previously, Dell’Aquila and
associates10 reported satisfactory clinical outcomes andThe Journal of Thoracic and Carhemodynamic performance in 50 patients who underwent
AVR with the Trifecta prosthesis. Our study differs from
these previous investigations by including comparison
groups of 2 other types of pericardial aortic valves in a
full range of valve sizes, and our data indicate a small but
statistically significant hemodynamic advantage for the
Trifecta valve in all labeled sizes.
Our results contrast with those from the recent study by
Wendt and associates,11 who compared early hemodynamic
performance of the Trifecta aortic prosthesis with that of the
Perimount Magna and Magna Ease prostheses. First, these
investigators examined Doppler echocardiographic data
from predischarge studies and from examinations per-
formed 6 months postoperatively. There were no important
differences in mean gradients or EOAs between the 2 time
points. Their data also demonstrated a slightly lower mean
gradient with the Trifecta prosthesis than with the other
pericardial valves (9.1 vs 11.2 mm Hg for the Perimount
Magna and 14.0 mm Hg for the Magna Ease). However,
there were significant differences in the preoperative char-
acteristics of patients receiving the 3 valves, so further
exploration of hemodynamic performance by multivariate
covariance analysis was performed, which showed no influ-
ence of prosthesis type on mean pressure gradient or aortic
valve area. In our study, although patients who received the
Mitroflow valve had more combined procedures and risk
factors, there were no important differences in baseline
characteristics that might have influenced the gradients or
valve areas. The study byWendt and colleagues11 is unusual
because the operative (30-day) mortality for the Trifecta
valve was 8.3%.
The Doppler echocardiographic assessment of EOA and
EOAI is a useful measure of prosthetic valve functiondiovascular Surgery c Volume 148, Number 5 1943
TABLE 4. Predischarge echocardiographic results for 1436 patients who underwent aortic valve replacement with 1 of 3 bovine bioprostheses*
Finding
Bioprosthesis (N ¼ 1436)
P valueTrifecta (n ¼ 196) Mitroflow (n ¼ 1135) Perimount Magna (n ¼ 105)
Overall (n ¼ 196) (n ¼ 1135) (n ¼ 105)
Preoperative LVOT index, cm 1.18  0.1 1.17  0.1 1.17  0.2 .79
Postoperative AV mean gradient, mm Hg 11.4  4.2 16.9  6.7 14.1  5.4 <.001
Postoperative EOA, cm2 2.22  0.7 1.85  0.5 2.09  0.5 <.001
Postoperative EOAI, cm2/m2 1.14  0.3 0.96  0.3 1.07  0.3 <.001
Valve size 19 mm (n ¼ 23) (n ¼ 46) (n ¼ 5)
Preoperative LVOT index, cm 1.21  0.1 1.22  0.1 1.19  0.1 .77
Postoperative AV mean gradient, mm Hg 15.1  5.0 21.3  9.1 21.4  7.7 .011
Postoperative EOA, cm2 1.53  0.3 1.23  0.3 1.26  0.2 .001
Postoperative EOAI, cm2/m2 0.91  0.2 0.78  0.3 0.76  0.2 .04
Valve size 21 mm (n ¼ 48) (n ¼ 336) (n ¼ 31)
Preoperative LVOT index, cm 1.15  0.1 1.19  0.1 1.23  0.2 .08
Postoperative AV mean gradient, mm Hg 12.0  4.1 18.4  6.5 15.9  5.6 <.001
Postoperative EOA, cm2 1.84  0.4 1.52  0.4 1.73  0.2 <.001
Postoperative EOAI, cm2/m2 1.02  0.3 0.87  0.2 0.98  0.2 <.001
Valve size 23 mm (n ¼ 62) (n ¼ 423) (n ¼ 32)
Preoperative LVOT index, cm 1.13  0.1 1.15  0.1 1.13  0.2 .25
Postoperative AV mean gradient, mm Hg 11.2  3.4 17.2  6.2 14.2  4.9 <.001
Postoperative EOA, cm2 2.23  0.5 1.83  0.4 2.01  0.3 <.001
Postoperative EOAI, cm2/m2 1.12  0.3 0.94  0.2 1.04  0.2 <.001
Valve size 25 mm (n ¼ 42) (n ¼ 262) (n ¼ 29)
Preoperative LVOT index, cm 1.21  0.1 1.15  0.1 1.12  0.1 .01
Postoperative AV mean gradient, mm Hg 10.0  3.7 14.2  4.9 11.8  3.6 <.001
Postoperative EOA, cm2 2.73  0.5 2.28  0.5 2.47  0.5 <.001
Postoperative EOAI, cm2/m2 1.33  0.3 1.1  0.3 1.17  0.2 <.001
Valve sizes 27 mm, 29 mm, and 31 mm (n ¼ 18) (n ¼ 68) (n ¼ 8)
Preoperative LVOT index, cm 1.29  0.2 1.22  0.2 1.31  0.2 .18
Postoperative AV mean gradient, mm Hg 8.1  3.1 13.9  4.8 11.3  5.0 <.001
Postoperative EOA, cm2 3.2  0.8 2.48  0.5 2.8  0.5 .002
Postoperative EOAI, cm2/m2 1.51  0.3 1.18  0.3 1.33  0.3 <.001
AV, Aortic valve; EOA, effective orifice area; EOAI, effective orifice area index; LVOT, left ventricular outflow tract. *Values are mean  standard deviation unless indicated
otherwise.
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assessment of peak or mean transvalvular gradients. The
EOAI also is a useful measure of PPM, which has been
shown to affect short- and long-term survival.17,21
Moderate PPM might be tolerated in elderly patients and
those of smaller body size,22 but severe PPM has been
shown to be particularly deleterious in young athletes and
in high-risk patients with poor left ventricular function.21
Jamieson and colleagues23 reported reduced 10-year sur-
vival of patients with moderate and severe PPM after Mitro-
flow AVR (12.9%) compared with patients with no PPM
(28.8%). In our study, risk of severe PPM with the Trifecta
valve was only 1.3%, which was lower than the risk with
the other 2 pericardial bioprostheses.
In this report, transprosthetic gradients and valve areas
may not correspond precisely to previously published
data because our study used early postoperative Doppler
echocardiogram measurements obtained at a mean of
4.7  2.6 days after operation. Increased circulating cate-
cholamines and dilutional anemia might have affected early1944 The Journal of Thoracic and Cardiovascular Surpostoperative mean gradient and peak velocity.20 However,
these potentially confounding conditions would not be
expected to affect EOA and EOAI. Mid-term follow-up
will be necessary before definitive conclusions can be
drawn regarding postdischarge hemodynamic differences
among these 3 devices.
Study Limitations
We studied early hemodynamics at rest for all 3 valves at
hospital discharge. It is possible that minor differences
might occur after exercise assessment; however, in clinical
practice, the measurement of resting hemodynamics with
additional maneuvers is a commonly accepted standard
for evaluation of prosthetic valve function early after sur-
gery.16 The external diameter of the sewing rings may differ
from the labeled valve size, and without direct measurement
of LVOT dimension using a universal sizer at surgery, one
might argue that valves with differing internal dimensions
were compared using labeled valve size alone.3 To address
this potential bias, we compared the preoperative LVOTgery c November 2014
FIGURE 1. Discharge echocardiographic findings for 1436 patients strat-
ified by valve size for the Trifecta (St Jude Medical, St Paul, Minn), Mitro-
flow (Sorin Group, Milan, Italy), and Perimount Magna (Edwards
Lifesciences Corp, Irvine, Calif) bovine aortic valve bioprostheses. Top
of box-and-whiskers plots shows that the averagemean gradient was signif-
icantly lower across valve sizes (19 mm, 21 mm, 23 mm, 25 mm, and 27
mm) for the Trifecta valve. Middle shows that the mean EOAwas signifi-
cantly greater across valve sizes for the Trifecta valve. Bottom shows that
the mean EOAI was significantly higher across valve sizes for the Trifecta
valve. Mean and median are represented by the diamond and horizontal
line, respectively, inside each colored box. Area between the top and
bottom borders (ie, whiskers) represents the middle 50% of the data.
EOA, Effective orifice area; EOAI, effective orifice area index; MG,
mean gradient.
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Dindex of the patients for each valve size and found no
important differences.CONCLUSIONS
The early hemodynamic performance of the new Trifecta
bioprosthesis compared with that of 2 better known devices
was favorable at the time of discharge from the hospital.The Journal of Thoracic and CarLongitudinal clinical and echocardiographic assessments
will be necessary to determine whether these small hemo-
dynamic differences persist and influence mid- to late-
term clinical outcomes.
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